Harbour Investment Management LLC Trims Stake in Kenvue Inc. (NYSE:KVUE)

Harbour Investment Management LLC trimmed its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 19.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 55,807 shares of the company's stock after selling 13,596 shares during the period. Harbour Investment Management LLC's holdings in Kenvue were worth $1,191,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Assetmark Inc. grew its holdings in Kenvue by 29.9% during the 3rd quarter. Assetmark Inc. now owns 67,796 shares of the company's stock worth $1,568,000 after acquiring an additional 15,593 shares during the period. Atria Investments Inc lifted its position in shares of Kenvue by 13.8% during the 3rd quarter. Atria Investments Inc now owns 111,326 shares of the company's stock worth $2,575,000 after buying an additional 13,500 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Kenvue during the 3rd quarter worth approximately $213,000. Victory Capital Management Inc. raised its holdings in shares of Kenvue by 66.2% in the 3rd quarter. Victory Capital Management Inc. now owns 1,328,074 shares of the company's stock worth $30,718,000 after purchasing an additional 528,849 shares during the period. Finally, KBC Group NV raised its holdings in shares of Kenvue by 114.0% in the 3rd quarter. KBC Group NV now owns 966,160 shares of the company's stock worth $22,348,000 after purchasing an additional 514,580 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 0.6 %

NYSE:KVUE traded up $0.15 on Wednesday, hitting $23.49. The stock had a trading volume of 9,646,894 shares, compared to its average volume of 16,084,529. The company has a fifty day moving average price of $21.94 and a two-hundred day moving average price of $22.41. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $44.89 billion, a price-to-earnings ratio of 44.31, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's dividend payout ratio is presently 154.72%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Canaccord Genuity Group upped their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Finally, Barclays lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of "Hold" and an average target price of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.